Centiva Capital’s CRISPR Therapeutics CRSP Stock Holding History

Centiva Capital’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,987	Closed	-$222K	–	1261
2021 Q3	$222K	Buy	+1,987	New	+$250K	0.01%	898

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Centiva Capital's CRSP Position: Q4 2021 in Review

Centiva Capital sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 1,987 shares — an estimated $222K sold.

Centiva Capital first reported a position in CRSP in Q3 2021 and held it in 1 quarter. The position peaked at $222K in Q3 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

Centiva Capital reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
Centiva Capital sold 1,987 CRISPR Therapeutics shares in Q4 2021, an estimated $222K.
Centiva Capital first reported a position in CRISPR Therapeutics in Q3 2021 and held it in 1 quarter.
Centiva Capital's CRISPR Therapeutics position peaked at $222K in Q3 2021.
446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Centiva Capital's 13F filing for Q4 2021, filed 14 Feb 2022.